Published in Arch Neurol on June 01, 2002
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk. Parkinsonism Relat Disord (2015) 1.70
Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. J Neural Transm (Vienna) (2011) 1.19
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med (2013) 1.18
Accumulation of nuclear DNA damage or neuron loss: molecular basis for a new approach to understanding selective neuronal vulnerability in neurodegenerative diseases. DNA Repair (Amst) (2008) 1.04
Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol (2007) 1.01
Microglia activation is related to substantia nigra echogenicity. J Neural Transm (Vienna) (2010) 1.01
Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int (2014) 1.00
Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography. J Neurol (2014) 0.99
Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol (2013) 0.96
Neuroimaging in Parkinson's disease. Neurotherapeutics (2011) 0.95
Neuroimaging in the early diagnosis of neurodegenerative disease. Transl Neurodegener (2012) 0.91
Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. J Neural Transm (Vienna) (2007) 0.91
The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurol (2008) 0.90
Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia. J Neurol (2005) 0.90
Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open (2013) 0.89
Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. J Neurol (2007) 0.87
Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systematic review. J Neurol (2009) 0.85
Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. J Psychiatry Neurosci (2011) 0.85
Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population. J Neural Transm (Vienna) (2008) 0.84
Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency. Eur Arch Psychiatry Clin Neurosci (2008) 0.84
Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound. Ultrasound Med Biol (2010) 0.84
Sublethal RNA oxidation as a mechanism for neurodegenerative disease. Int J Mol Sci (2008) 0.83
Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson's disease patients. J Neural Transm (Vienna) (2009) 0.83
Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS One (2013) 0.83
Transcranial sonography for diagnosis of Parkinson's disease. BMC Neurol (2010) 0.83
Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol (2007) 0.83
Substantia nigra echogenicity in Parkinson's disease: relation to serum iron and C-reactive protein. J Neural Transm (Vienna) (2011) 0.82
Brain tissue echogenicity--implications for substantia nigra studies in parkinsonian patients. J Neural Transm (Vienna) (2011) 0.82
Quantitative susceptibility mapping by inversion of a perturbation field model: correlation with brain iron in normal aging. IEEE Trans Med Imaging (2014) 0.82
Postnatal decrease in substantia nigra echogenicity. Implications for the pathogenesis of Parkinson's disease. J Neurol (2004) 0.82
Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis. Sci Rep (2016) 0.81
Parkinson's disease-like midbrain hyperechogenicity is frequent in amyotrophic lateral sclerosis. J Neurol (2012) 0.81
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J (2010) 0.81
Combination of olfactory test and substantia nigra transcranial sonopraphy in the differential diagnosis of Parkinson's disease: a pilot study from China. Transl Neurodegener (2012) 0.81
Relation of risk factors and putative premotor markers for Parkinson's disease. J Neural Transm (Vienna) (2011) 0.81
The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis (2015) 0.81
Prodromal non-motor symptoms of Parkinson's disease. Neuropsychiatr Dis Treat (2007) 0.80
Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm (Vienna) (2012) 0.80
In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage. J Neural Transm (Vienna) (2006) 0.80
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. Neurotherapeutics (2009) 0.80
Iron and Oxidative Stress in Parkinson's Disease: An Observational Study of Injury Biomarkers. PLoS One (2016) 0.79
Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J Neural Transm (Vienna) (2009) 0.79
Protocol of a prospective study on the diagnostic value of transcranial duplex scanning of the substantia nigra in patients with parkinsonian symptoms. BMC Neurol (2007) 0.79
Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. J Neurol (2013) 0.78
Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord (2011) 0.78
The diagnostic value of midbrain hyperechogenicity in ALS is limited for discriminating key ALS differential diagnoses. BMC Neurol (2015) 0.78
Basal ganglia hyperechogenicity does not distinguish between patients with primary dystonia and healthy individuals. J Neurol (2010) 0.77
Brain Iron Metabolism Dysfunction in Parkinson's Disease. Mol Neurobiol (2016) 0.77
Sonographic basal ganglia alterations are related to non-motor symptoms in multiple sclerosis. J Neurol (2010) 0.76
Hand function is impaired in healthy older adults at risk of Parkinson's disease. J Neural Transm (Vienna) (2014) 0.76
Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder. J Psychiatry Neurosci (2010) 0.76
Transcranial sonography in pantothenate kinase-associated neurodegeneration. J Neurol (2011) 0.76
Substantia nigra hyperechogenicity in healthy controls: a [¹⁸Fluoro] Dopa-PET follow-up study. J Neurol (2013) 0.76
Is there a need to redefine Parkinson's disease? J Neural Transm (Vienna) (2013) 0.76
Early diagnosis of Parkinson's disease. J Neurol (2006) 0.76
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener (2017) 0.75
Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Transm (Vienna) (2016) 0.75
Abnormal Echogenicity of the Substantia Nigra, Raphe Nuclei, and Third-Ventricle Width as Markers of Cognitive Impairment in Parkinsonian Disorders: A Cross-Sectional Study. Parkinsons Dis (2016) 0.75
Substantia nigra hyperechogenicity in hypokinetic Huntington's disease patients. J Neurol (2015) 0.75
Transcranial Sonographic Alterations of Substantia Nigra and Third Ventricle in Parkinson's Disease with or without Dementia. Chin Med J (Engl) (2017) 0.75
Transcranial sonography image characteristics in different Parkinson's disease subtypes. Neurol Sci (2017) 0.75
Movement disorders: neurodevelopment and neurobehavioural expression. J Neural Transm (Vienna) (2006) 0.75
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol (2002) 6.92
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev (2005) 3.29
EphB-ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion. Nat Cell Biol (2003) 3.26
Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol (2007) 2.83
Small fibre pathology in patients with fibromyalgia syndrome. Brain (2013) 2.72
Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol (2004) 2.59
Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med (2006) 2.59
Hippocampal plasticity requires postsynaptic ephrinBs. Nat Neurosci (2003) 2.37
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain (2010) 2.35
Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PLoS Biol (2008) 2.35
EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol Cell (2002) 2.31
Control of skeletal patterning by ephrinB1-EphB interactions. Dev Cell (2003) 2.11
Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron (2002) 2.03
Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85
Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol (2007) 1.72
Cooperation between GDNF/Ret and ephrinA/EphA4 signals for motor-axon pathway selection in the limb. Neuron (2006) 1.71
MR imaging in the differential diagnosis of neurogenic foot drop. AJNR Am J Neuroradiol (2003) 1.70
Neuron-glia communication via EphA4/ephrin-A3 modulates LTP through glial glutamate transport. Nat Neurosci (2009) 1.70
Transient dystonia following magnetic resonance imaging in a patient with deep brain stimulation electrodes for the treatment of Parkinson disease. Case report. J Neurosurg (2003) 1.68
Signaling from axon guidance receptors. Cold Spring Harb Perspect Biol (2010) 1.62
GDNF acts as a chemoattractant to support ephrinA-induced repulsion of limb motor axons. Curr Biol (2010) 1.59
Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol (2006) 1.56
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
EphA4-dependent axon guidance is mediated by the RacGAP alpha2-chimaerin. Neuron (2007) 1.48
Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol Cell Biol (2007) 1.48
Regulation of EphA 4 kinase activity is required for a subset of axon guidance decisions suggesting a key role for receptor clustering in Eph function. Neuron (2005) 1.44
The two sides of associative plasticity in writer's cramp. Brain (2006) 1.43
The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2004) 1.42
c-Jun in Schwann cells promotes axonal regeneration and motoneuron survival via paracrine signaling. J Cell Biol (2012) 1.38
Temporary occlusion of associative motor cortical plasticity by prior dynamic motor training. Cereb Cortex (2005) 1.36
Timing-dependent plasticity in human primary somatosensory cortex. J Physiol (2005) 1.35
Serine phosphorylation of ephrinB2 regulates trafficking of synaptic AMPA receptors. Nat Neurosci (2008) 1.34
Transgenic mouse proteomics identifies new 14-3-3-associated proteins involved in cytoskeletal rearrangements and cell signaling. Mol Cell Proteomics (2006) 1.32
A common neural basis for receptive and expressive communication of pleasant facial affect. Neuroimage (2005) 1.24
Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage (2009) 1.23
In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord (2005) 1.23
Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol (2007) 1.22
Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener Dis (2004) 1.21
Genes associated with Parkinson syndrome. J Neurol (2008) 1.21
Distinct requirements for TrkB and TrkC signaling in target innervation by sensory neurons. Genes Dev (2002) 1.20
Progressive postnatal motoneuron loss in mice lacking GDF-15. J Neurosci (2009) 1.20
Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord (2005) 1.19
MRI of peripheral nerve degeneration and regeneration: correlation with electrophysiology and histology. Exp Neurol (2004) 1.19
Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth. J Cell Biol (2005) 1.18
Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol (2009) 1.17
The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord (2010) 1.16
Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J Peripher Nerv Syst (2011) 1.15
Immunohistochemical evidence of seizure-induced activation of trkB receptors in the mossy fiber pathway of adult mouse hippocampus. J Neurosci (2002) 1.15
The Rab5 guanylate exchange factor Rin1 regulates endocytosis of the EphA4 receptor in mature excitatory neurons. Proc Natl Acad Sci U S A (2008) 1.15
Subthalamic nucleus stimulation affects a frontotemporal network: a PET study. Ann Neurol (2003) 1.15
Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol (2008) 1.13
A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One (2010) 1.13
RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc Natl Acad Sci U S A (2007) 1.11
FLRT2 and FLRT3 act as repulsive guidance cues for Unc5-positive neurons. EMBO J (2011) 1.11
Effects of methylphenidate on multiple components of attention in children with attention deficit hyperactivity disorder. Psychopharmacology (Berl) (2006) 1.11
Release of full-length EphB2 receptors from hippocampal neurons to cocultured glial cells. J Neurosci (2006) 1.10
Muscle magnetic resonance imaging of denervation and reinnervation: correlation with electrophysiology and histology. Exp Neurol (2004) 1.10
Executive deficits are related to the inferior frontal junction in early dementia. Brain (2011) 1.09
Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry (2009) 1.08
Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol (2008) 1.08
Inactivation of VCP/ter94 suppresses retinal pathology caused by misfolded rhodopsin in Drosophila. PLoS Genet (2010) 1.08
Effects of gum chewing on memory and attention: reply to Scholey (2004). Appetite (2004) 1.08
"Subcellular proteomics" of neuromelanin granules isolated from the human brain. Mol Cell Proteomics (2005) 1.08
Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than "depressive". Biol Psychiatry (2003) 1.08
Executive functions in children with dyslexia. Dyslexia (2005) 1.07
Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons. PLoS Biol (2010) 1.07
Characteristics of sensory trick-like manoeuvres in jaw-opening dystonia. Mov Disord (2007) 1.07
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging (2011) 1.06
Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 1.05
Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J Neurosci (2003) 1.05
Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling. J Neurosci (2007) 1.05
Morvan's syndrome: clinical, laboratory, and in vitro electrophysiological studies. Muscle Nerve (2004) 1.05
The glucocorticoid receptor gene exon 1-F promoter is not methylated at the NGFI-A binding site in human hippocampus. World J Biol Psychiatry (2007) 1.05
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. Am J Surg Pathol (2003) 1.04
Diminished cooperativeness of psychopaths in a prisoner's dilemma game yields higher rewards. J Abnorm Psychol (2008) 1.04
Camptocormia in Parkinson's disease mimicked by focal myositis of the paraspinal muscles. Mov Disord (2002) 1.03
Tyrosine phosphorylation sites in ephrinB2 are required for hippocampal long-term potentiation but not long-term depression. J Neurosci (2007) 1.02
Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs (2003) 1.02
Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol (2004) 1.02
EphB receptors and ephrin-B3 regulate axon guidance at the ventral midline of the embryonic mouse spinal cord. J Neurosci (2006) 1.01
Mesodermal cell types induce neurogenesis from adult human hippocampal progenitor cells. J Neurochem (2006) 1.01
Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res (2007) 1.01
Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci (2010) 1.01
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis (2013) 1.01
Role for ephrinB2 in postnatal lung alveolar development and elastic matrix integrity. Dev Dyn (2008) 1.00
Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J (2005) 1.00
Structurally encoded intraclass differences in EphA clusters drive distinct cell responses. Nat Struct Mol Biol (2013) 1.00
Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells (2005) 1.00
Risky behavior in gambling tasks in individuals with ADHD--a systematic literature review. PLoS One (2013) 1.00
Met signaling is required for recruitment of motor neurons to PEA3-positive motor pools. Neuron (2003) 0.99
Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochem Int (2006) 0.99